FOLH1 and posterior cortical atrophy: Complementing these findings, a study from Israel by Golan et al. (NCT04432015) investigated neoadjuvant 177Lu-PSMA-I&T, a different PSMA-targeting ligand, in 11 men with high-risk localized PCa [27].